Clinical Trials on KRAS Protein Variant in Finland

Total 314 results

National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Novo Nordisk A/S

Enrolling by invitation

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

Haemophilia B

Canada, United Kingdom, Czechia, Germany, Greece, Austria, Belgium, Croatia, Denmark, Finland, Norway, Portugal
Oasmia Pharmaceutical AB

Completed

Study of Paclitaxel in Patients With Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

Ukraine, Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, Hungary, Latvia, Lithuania, Romania, Russian Federation, Serbia, Slovakia, Sweden
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Primary Peritoneal Cavity Cancer | Brenner Tumor | Recurrent Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Mixed Epithelial Carcinoma | Ovarian...

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

Ovarian Clear Cell Cystadenocarcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States, Korea, Republic of, Japan
Tesaro, Inc.
Myriad Genetics, Inc.; Facing Our Risk of Cancer Empowered

Completed

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA)

Ovarian Neoplasms | Ovarian Cancer

United States, Canada
Celgene

Completed

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States, Canada, Germany, Spain, Denmark, Netherlands, Finland, Italy
NCIC Clinical Trials Group

Completed

ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer

Ovarian Cancer

United States, Canada, United Kingdom
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Primary Peritoneal Cancer... and other conditions

United States
Arcagy Research
Belgian Gynaecological Oncology Group; Grupo Español de Investigación en Cáncer... and other collaborators

Completed

Platine, Avastin and OLAparib in 1st Line (PAOLA-1)

Ovarian Cancer

France, Germany, Austria, Denmark, Italy, Japan, Finland, Spain, Monaco, Sweden, Belgium
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Active, not recruiting

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Ovarian Neoplasms | Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

United States, Netherlands, Spain, Finland, Italy, Poland, Belgium, Canada, France, Germany, Romania, Ukraine, Norway, United Kingdom, Israel, Greece, Denmark, Belarus, Czechia
Novartis Pharmaceuticals

Active, not recruiting

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Belgium, Italy, Korea, Republic of, Hong Kong, Israel, Finland, Spain, Japan, United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Adenocarcinoma

United States, Korea, Republic of
Eli Lilly and Company

Completed

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Ovarian Cancer

United States, Israel, Spain, Korea, Republic of, Australia, Belgium, United Kingdom, Italy
Mario Negri Institute for Pharmacological Research
PharmaMar; Averion International Corporation

Completed

INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer (INOVATYON)

Ovarian Cancer

Austria, Belgium, Norway, Spain, Finland, United Kingdom, Italy, Denmark, Germany, Netherlands, Switzerland
Unither Pharmaceuticals

Terminated

Clinical Trial for Ovarian Cancer (OvaRex®)

Ovarian Cancer

United States
Hoffmann-La Roche

Completed

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Ovarian Cancer

Belgium, Denmark, France, Germany, Portugal, Spain, Turkey, Bosnia and Herzegovina, Italy, Sweden, Finland, Netherlands, Norway, Greece
Swedish Orphan Biovitrum

Active, not recruiting

A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health (A-MORE)

Hemophilia A

Spain, Germany, Czechia, Italy, Estonia, Finland, Greece, Netherlands, Saudi Arabia, Slovenia, Sweden, Switzerland, United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy

Fallopian Tube Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Malignant Ovarian Brenner Tumor and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Malignant Ovarian Endometrioid Tumor | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive Ovarian Carcinoma | Fallopian Tube High Grade Serous Adenocarcinoma and other conditions

United States
AGO Study Group
European Organisation for Research and Treatment of Cancer - EORTC; NCIC Clinical...

Completed

Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy

Ovarian Cancer

Canada, United States
Acrivon Therapeutics
GOG Foundation

Recruiting

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Platinum-resistant Ovarian Cancer | Urothelial Carcinoma | Endometrial Adenocarcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation | Endometrioid Stromal Sarcoma

United States
National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
Eisai Inc.

Completed

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Platinum-Sensitive Ovarian Cancer in First Relapse

United States, Italy, United Kingdom, Germany, Spain, Belgium, Japan
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Ovarian Gynandroblastoma | Ovarian Sertoli-Leydig Cell Tumor | Ovarian Sex Cord Tumor With Annular Tubules | Ovarian Steroid Cell Tumor | Ovarian Granulosa Cell Tumor | Ovarian Sex Cord-Stromal Tumor | Ovarian Sex Cord-Stromal Tumor, Not Otherwise Specified

United States
Fondazione Angelo Bianchi Bonomi
Sintesi Research Srl

Active, not recruiting

Type 3 Von Willebrand International Registries Inhibitor Prospective Study (3WINTERSIPSEXT)

Type 3 Von Willebrand's Disease

Finland, France, Germany, Hungary, Iran, Islamic Republic of, Italy, Netherlands, Spain, Sweden, United Kingdom
Bayer

Completed

Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

Ovarian Neoplasms

Poland, Belgium, Spain, Hong Kong, Korea, Republic of, Canada, Italy, Singapore, Germany, United States, Netherlands, France, Japan, Finland
Octapharma

Completed

Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A

Severe Haemophilia A

France, Japan, United States, Canada, Croatia, Finland, Netherlands, North Macedonia, Slovenia
ModernaTX, Inc.

Terminated

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Ovarian Cancer | Relapsed/Refractory Solid Tumor Malignancies or Lymphoma

United States
Tarix Pharmaceuticals
Constant Therapeutics LLC

Terminated

Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients (TXA127-PBSC)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Hodgkin Disease

United States
Sanofi

Recruiting

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Plasma Cell Myeloma

Czechia, Australia, Chile, France, Spain, United States, Brazil, China, Greece, Japan, Korea, Republic of, Sweden, Taiwan, Finland, Italy, Russian Federation
Menarini Group

Terminated

Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (MIMOSA)

Ovarian Cancer

United States, Spain, Germany, Belgium, France, Czech Republic, Hungary, Italy, Poland
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
ImmunoGen, Inc.

Active, not recruiting

IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Ovarian Cancer

United States, United Kingdom, Belgium, Spain, Canada, Georgia
GOG Foundation
National Cancer Institute (NCI)

Completed

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
ImmunoGen, Inc.
Gynecologic Oncology Group

Completed

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

United States, France, Canada, Spain, Switzerland, Belgium, Italy, United Kingdom, Ireland, Russian Federation, Bosnia and Herzegovina, Czechia, Serbia
AstraZeneca
European Network of Gynaecological Oncological Trial Groups (ENGOT); Myriad... and other collaborators

Active, not recruiting

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)

Advanced Ovarian Cancer

Canada, Denmark, Germany, Italy, Spain, United States, Belgium, Poland, France, Korea, Republic of, Brazil, Hungary, Japan, Peru, Turkey, China, Austria, Bulgaria, Finland, Romania
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States, Korea, Republic of, Canada
Brown University
Bristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...

Active, not recruiting

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Extra Renal Origin | Clear Cell Adenocarcinoma

United States
Tesaro, Inc.
Gynecologic Oncology Group; European Network of Gynaecological Oncological... and other collaborators

Active, not recruiting

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Ovarian Neoplasms

United States, Spain, Finland, Czechia, Italy, Denmark, Germany, Belgium, Israel, Canada, Russian Federation, Sweden, United Kingdom, Poland, Ireland, Ukraine, France, Norway, Switzerland, Hungary
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

Hemophilia A

Poland, Belgium, France, Italy, Spain, United States, Australia, Netherlands, New Zealand, Sweden, Germany, Finland, Hungary
Mersana Therapeutics
IQVIA Biotech; PSI CRO

Recruiting

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Platinum Resistant Ovarian Cancer | Non Small Cell Lung Cancer Metastatic

United States, Spain, United Kingdom, Australia, France, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, Hungary, Italy, Lithuania, New Zealand, Norway, Poland, Sweden
ImmunoGen, Inc.
Gynecologic Oncology Group; European Network of Gynaecological Oncological...

Active, not recruiting

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Canada, Germany, China, France, Korea, Republic of, Belgium, United Kingdom, Serbia, Spain, Australia, Israel, Italy, Taiwan, Czechia, Bulgaria, Netherlands, Portugal, Poland, Russian Federation, Ukraine
Novartis Pharmaceuticals

Active, not recruiting

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Ovarian Cancer

United States, Italy, United Kingdom, Malaysia, Taiwan, Turkey, Belgium, Canada, Spain, Singapore, Austria, Denmark, Korea, Republic of, Australia, China, France, Netherlands, Russian Federation, Germany, Argentina, Mexico, Finland, Portuga... and more
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass

Ovarian Cancer | Fallopian Tube Cancer

United States
Janssen-Cilag International NV

Completed

Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (OPTIMRETREAT)

Multiple Myeloma

France, Poland, Belgium, Germany, Israel, Portugal, Turkey, Finland, Sweden, Netherlands, Norway
Pfizer

Available

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma (MAGNETISMM17)

Multiple Myeloma

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT); US Oncology... and other collaborators

Completed

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Ovarian Neoplasms | Platinum Sensitive Ovarian Cancer

United States, Belgium, Sweden, Germany, Israel, Austria, Canada, Denmark, Spain, Italy, United Kingdom, Poland, France, Hungary, Norway

Clinical Trials on KRAS Protein Variant in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations